Long-Term Use of Oclacitinib Maleate for the Management of Pemphigus Foliaceus in a Miniature Donkey.

Oclacitinib maleate safely and effectively manages pemphigus foliaceus in equines long-term.

This case report documents the successful long-term management of pemphigus foliaceus in a 6-year-old miniature donkey using oclacitinib maleate, a selective Janus kinase inhibitor. The patient presented with classic clinical signs including pruritus, scaling, crusting, and alopecia. Diagnosis was confirmed through history, clinical presentation, and histopathological examination. The donkey was treated with oclacitinib maleate monotherapy and combination therapy with low-dose prednisolone over a 4-year treatment period. Notably, the patient demonstrated excellent therapeutic response with no reported adverse effects or signs of toxicity throughout the extended treatment duration. This case is significant as it demonstrates oclacitinib's potential as an effective and safe therapeutic option for autoimmune dermatological conditions in equine patients, particularly miniature donkeys. The successful outcome suggests oclacitinib may provide an alternative or adjunctive treatment strategy for pemphigus foliaceus in horses and donkeys, potentially reducing reliance on corticosteroid monotherapy and its associated systemic side effects.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.